Use of sacubitril/valsartan in non-compaction cardiomyopathy: a case report
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (3), 1186-1189
- https://doi.org/10.1002/ehf2.12713
Abstract
The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non-compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM initially refractory to gold standard treatment and afterwards treated with sacubitril/valsartan and its improvements. This is a case report of a 48-year-old woman, presenting with NCCM heart failure, who had received standard guideline-directed medical therapy for 18 months without any improvement in clinical and echocardiographic parameters. After that period, sacubitril/valsartan was initiated. After 18 months of refractory usage of guideline-directed medical therapy, sacubitril/valsartan was started, and significant change in functional class (III to I) and important ventricular remodelling were achieved with an improvement of 29% in the ejection fraction, reduction of 7 mm in ventricular diastolic diameter, and mild to none mitral valve functional regurgitation. In this case report, sacubitril/valsartan use was associated with improvement of echocardiographic and clinical parameters in a patient with NCCM.This publication has 21 references indexed in Scilit:
- Left Ventricular NoncompactionJournal of the American College of Cardiology, 2016
- Isolated Noncompaction of the Left Ventricle in AdultsJournal of the American College of Cardiology, 2015
- Left ventricular non-compaction cardiomyopathyThe Lancet, 2015
- Reverse Remodeling in Systolic Heart FailureCardiology in Review, 2015
- Isolated left ventricular non-compaction cardiomyopathy in adultsJournal of Cardiology, 2015
- Adult Left Ventricular NoncompactionJACC: Cardiovascular Imaging, 2014
- Evaluation and Management of Left Ventricular Noncompaction CardiomyopathyCurrent Heart Failure Reports, 2014
- Left Ventricular NoncompactionJournal of the American College of Cardiology, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction: A Meta-Analytic ApproachJournal of the American College of Cardiology, 2010